|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rodriguez-Vida A, Hutson TE, Bellmunt J
and Strijbos MH: New treatment options for metastatic renal cell
carcinoma. ESMO Open. 2:e0001852017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Motzer RJ, Hutson TE, Cella D, Reeves J,
Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et
al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
N Engl J Med. 369:722–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sternberg CN, Davis ID, Mardiak J,
Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA,
Kavina A, et al: Pazopanib in locally advanced or metastatic renal
cell carcinoma: Results of a randomized phase III trial. J Clin
Oncol. 28:1061–1068. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eldar-Finkelman H: Glycogen synthase
kinase 3: An emerging therapeutic target. Trends Mol Med.
8:126–132. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schlender KK, Beebe SJ, Willey JC, Lutz SA
and Reimann EM: Isolation and characterization of cyclic
AMP-independent glycogen synthase kinase from rat skeletal muscle.
Biochim Biophys Acta. 615:324–340. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nagini S, Sophia J and Mishra R: Glycogen
synthase kinases: Moonlighting proteins with theranostic potential
in cancer. Semin Cancer Biol. 56:25–36. 2019. View Article : Google Scholar
|
|
9
|
de Groot RP, Auwerx J, Bourouis M and
Sassone-Corsi P: Negative regulation of Jun/AP-1: Conserved
function of glycogen synthase kinase 3 and the drosophila kinase
shaggy. Oncogene. 8:841–847. 1993.PubMed/NCBI
|
|
10
|
Sears R, Nuckolls F, Haura E, Taya Y,
Tamai K and Nevins JR: Multiple Ras-dependent phosphorylation
pathways regulate Myc protein stability. Genes Dev. 14:2501–2514.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Diehl JA, Cheng M, Roussel MF and Sherr
CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis
and subcellular localization. Genes Dev. 12:3499–3511. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rubinfeld B, Albert I, Porfiri E, Fiol C,
Munemitsu S and Polakis P: Binding of GSK3beta to the
APC-beta-catenin complex and regulation of complex assembly.
Science. 272:1023–1026. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Walz A, Ugolkov A, Chandra S, Kozikowski
A, Carneiro BA, O'Halloran TV, Giles FJ, Billadeau DD and Mazar AP:
Molecular pathways: Revisiting glycogen synthase kinase-3β as a
target for the treatment of cancer. Clin Cancer Res. 23:1891–1897.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bilim V, Ougolkov A, Yuuki K, Naito S,
Kawazoe H, Muto A, Oya M, Billadeau D, Motoyama T and Tomita Y:
Glycogen synthase kinase-3: A new therapeutic target in renal cell
carcinoma. Br J Cancer. 101:2005–2014. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hilliard TS, Gaisina IN, Muehlbauer AG,
Gaisin AM, Gallier F and Burdette JE: Glycogen synthase kinase 3β
inhibitors induce apoptosis in ovarian cancer cells and inhibit
in-vivo tumor growth. Anticancer Drugs. 22:978–985. 2011.PubMed/NCBI
|
|
16
|
Gaisina IN, Gallier F, Ougolkov AV, Kim
KH, Kurome T, Guo S, Holzle D, Luchini DN, Blond SY, Billadeau DD
and Kozikowski AP: From a natural product lead to the
identification of potent and selective
benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase
3beta inhibitors that suppress proliferation and survival of
pancreatic cancer cells. J Med Chem. 52:1853–1863. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ugolkov A, Qiang W, Bondarenko G, Procissi
D, Gaisina I, James CD, Chandler J, Kozikowski A, Gunosewoyo H,
O'Halloran T, et al: Combination treatment with the GSK-3 inhibitor
9-ING-41 and CCNU cures orthotopic chemoresistant glioblastoma in
patient-derived xenograft models. Transl Oncol. 10:669–678. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ugolkov AV, Bondarenko GI, Dubrovskyi O,
Berbegall AP, Navarro S, Noguera R, O'Halloran TV, Hendrix MJ,
Giles FJ and Mazar AP: 9-ING-41, a small-molecule glycogen synthase
kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs.
29:717–724. 2018.PubMed/NCBI
|
|
19
|
Ugolkov A, Gaisina I, Zhang JS, Billadeau
DD, White K, Kozikowski A, Jain S, Cristofanilli M, Giles F,
O'Halloran T, et al: GSK-3 inhibition overcomes chemoresistance in
human breast cancer. Cancer Lett. 380:384–392. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pal K, Cao Y, Gaisina IN, Bhattacharya S,
Dutta SK, Wang E, Gunosewoyo H, Kozikowski AP, Billadeau DD and
Mukhopadhyay D: Inhibition of GSK-3 induces differentiation and
impaired glucose metabolism in renal cancer. Mol Cancer Ther.
13:285–296. 2014. View Article : Google Scholar :
|
|
21
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cormier KW and Woodgett JR: Recent
advances in understanding the cellular roles of GSK-3. F1000Res.
6:2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Morais C, Gobe G, Johnson DW and Healy H:
The emerging role of nuclear factor kappa B in renal cell
carcinoma. Int J Biochem Cell Biol. 43:1537–1549. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ougolkov AV, Bone ND, Fernandez-Zapico ME,
Kay NE and Billadeau DD: Inhibition of glycogen synthase kinase-3
activity leads to epigenetic silencing of nuclear factor kappaB
target genes and induction of apoptosis in chronic lymphocytic
leukemia B cells. Blood. 110:735–742. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ougolkov AV, Fernandez-Zapico ME, Savoy
DN, Urrutia RA and Billadeau DD: Glycogen synthase kinase-3beta
participates in nuclear factor kappaB-mediated gene transcription
and cell survival in pancreatic cancer cells. Cancer Res.
65:2076–2081. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kawazoe H, Bilim VN, Ugolkov AV, Yuuki K,
Naito S, Nagaoka A, Kato T and Tomita Y: GSK-3 inhibition in vitro
and in vivo enhances antitumor effect of sorafenib in renal cell
carcinoma (RCC). Biochem Biophys Res Commun. 423:490–495. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye
WC, Zhang DM and Chen ZS: Autophagy and multidrug resistance in
cancer. Chin J Cancer. 36:522017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Abdel-Mohsen MA, Ahmed OA and El-Kerm YM:
BRCA1 gene mutations and influence of chemotherapy on autophagy and
apoptotic mechanisms in Egyptian breast cancer patients. Asian Pac
J Cancer Prev. 17:1285–1292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Park JM, Huang S, Wu TT, Foster NR and
Sinicrope FA: Prognostic impact of Beclin 1, p62/sequestosome 1 and
LC3 protein expression in colon carcinomas from patients receiving
5-fluorouracil as adjuvant chemotherapy. Cancer Biol Ther.
14:100–107. 2013. View Article : Google Scholar :
|
|
30
|
Gao S, Yang XJ, Zhang WG, Ji YW and Pan Q:
Mechanism of thalidomide to enhance cytotoxicity of temozolomide in
U251-MG glioma cells in vitro. Chin Med J (Engl). 122:1260–1266.
2009.
|
|
31
|
Sun A, Li C, Chen R, Huang Y, Chen Q, Cui
X, Liu H, Thrasher JB and Li B: GSK-3β controls autophagy by
modulating LKB1-AMPK pathway in prostate cancer cells. Prostate.
76:172–183. 2016. View Article : Google Scholar
|
|
32
|
Marchand B, Arsenault D, Raymond-Fleury A,
Boisvert FM and Boucher MJ: Glycogen synthase kinase-3 (GSK3)
inhibition induces prosurvival autophagic signals in human
pancreatic cancer cells. J Biol Chem. 290:5592–5605. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Motzer RJ, Tannir NM, McDermott DF, Arén
Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P,
Porta C, George S, et al: Nivolumab plus ipilimumab versus
sunitinib in advanced renal-cell carcinoma. N Engl J Med.
378:1277–1290. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
